Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> P2X purinergic receptor>>Filapixant

Filapixant Sale

(Synonyms: BAY 1902607) 目录号 : GC63444

Filapixant 是一种嘌呤受体拮抗剂,详细信息请参考专利文献 WO2016091776A1 中的化合物 348。Filapixant 是 Eliapixant 的活性对照品。

Filapixant Chemical Structure

Cas No.:1948232-63-0

规格 价格 库存 购买数量
5 mg
10 mg

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.


Quality Control & SDS

View current batch:


Filapixant is a purinoreceptor antagonist extracted from patent WO2016091776A1, example 348. Filapixant is the active reference substance of Eliapixant[1].

[1]. Davenport AJ, et, al. 1,3-thiazol-2-yl substituted benzamides. WO2016091776A1.

Chemical Properties

Cas No. 1948232-63-0 SDF
别名 BAY 1902607
分子式 C24H26F3N5O3S 分子量 521.56
溶解度 DMSO : 146.67 mg/mL (281.21 mM; Need ultrasonic) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。


1 mg 5 mg 10 mg
1 mM 1.9173 mL 9.5866 mL 19.1732 mL
5 mM 0.3835 mL 1.9173 mL 3.8346 mL
10 mM 0.1917 mL 0.9587 mL 1.9173 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。


动物体内配方计算器 (澄清溶液)

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
% DMSO % % Tween 80 % saline

Research Update

The P2X3 receptor antagonist Filapixant in patients with refractory chronic cough: a randomized controlled trial

Respir Res 2023 Apr 11;24(1):109.PMID:37041539DOI:10.1186/s12931-023-02384-8

Background: P2X3 receptor antagonists seem to have a promising potential for treating patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled study, we investigated the efficacy, safety, and tolerability of the novel selective P2X3 receptor antagonist Filapixant (BAY1902607) in patients with refractory chronic cough. Methods: Following a crossover design, 23 patients with refractory chronic cough (age: 60.4 ± 9.1 years) received ascending doses of Filapixant in one period (20, 80, 150, and 250 mg, twice daily, 4-days-on/3-days-off) and placebo in the other. The primary efficacy endpoint was the 24-h cough frequency on Day 4 of each dosing step. Further, subjective cough severity and health-related quality of life were assessed. Results: Filapixant at doses ≥ 80 mg significantly reduced cough frequency and severity and improved cough health-related quality of life. Reductions in 24-h cough frequency over placebo ranged from 17% (80 mg dose) to 37% (250 mg dose), reductions over baseline from 23% (80 mg) to 41% (250 mg) (placebo: 6%). Reductions in cough severity ratings on a 100-mm visual analog scale ranged from 8 mm (80 mg) to 21 mm (250 mg). No serious or severe adverse events or adverse events leading to discontinuation of treatment were reported. Taste-related adverse events occurred in 4%, 13%, 43%, and 57% of patients treated with Filapixant 20, 80, 150, and 250 mg, respectively, and in 12% treated with placebo. Conclusions: Filapixant proved to be efficacious, safe, and-apart from the occurrence of taste disturbances, especially at higher dosages-well tolerated during the short therapeutic intervention. Clinical trial registration EudraCT, eudract.ema.europa.eu, 2018-000129-29; ClinicalTrials.gov, NCT03535168.